

EQA round: E13/23 - Hormones 1

Deadline: 25.7.2023

Setup: groups - measurement principle, manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(306) 17-OH-progesterone	[nmol/L]				1							1	0	0
Sample A												1	0	0
Other					1	0						1		
														1x 2/66
Sample B												1	0	0
Other					1	0						1		
														1x 2/66
(303) Aldosterone	[nmol/L]				3							2	2	100
Sample A												2	2	100
Other					3	0						2		
														1x 1/36, 1x 2/66, 1x 4/164
Sample B												2	2	100
Other					3	0						2		
														1x 1/36, 1x 2/66, 1x 4/164
(307) DHEA-S	[µmol/L]				3							3	2	67
Sample A												3	2	67
Other					3	0						3		
														2x 4/12, 1x 4/60
Sample B												3	2	67
Other					3	0						3		
														2x 4/12, 1x 4/60
(302) 17-beta-estradiol	[pmol/L]				7							7	7	100
Sample A												7	7	100
Other					7	0						7		
														2x 4/1, 1x 4/12, 4x 4/60
Sample B												7	7	100
Other					7	0						7		
														2x 4/1, 1x 4/12, 4x 4/60
(200) Ferritin	[µg/L]				14							13	13	100
Sample A		536	110	21	14							13	13	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		628	49	7,8	5	0	CVPG	635	11	24%	482	788	5	
Other					9	0						8		
														2x 4/12, 3x 4/60, 1x 6/1, 1x 6/58, 2x 6/60
Sample B		579	120	22	14							13	13	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		677	16	2,3	5	0	CVPG	675	11	24%	513	837	5	
Other					9	0						8		
														2x 4/12, 3x 4/60, 1x 6/1, 1x 6/58, 2x 6/60
(301) Cortisol	[nmol/L]				6							6	6	100
Sample A												6	6	100
Other					6	0						6		
														2x 4/1, 2x 4/12, 2x 4/60
Sample B												6	6	100
Other					6	0						6		
														2x 4/1, 2x 4/12, 2x 4/60
(304) Progesterone	[nmol/L]				8							8	8	100
Sample A												8	8	100
Other					8	0						8		
														3x 4/1, 2x 4/12, 3x 4/60
Sample B												8	8	100
Other					8	0						8		
														3x 4/1, 2x 4/12, 3x 4/60
(121) Total T3	[nmol/L]				2							2	1	50
Sample A												2	2	100
Other					2	0						2		
														1x 4/1, 1x 4/12
Sample B												2	1	50
Other					2	0						2		
														1x 4/1, 1x 4/12
(125) Free T3	[pmol/L]				12							12	11	92
Sample A		14,7	3,1	21	12							12	11	92
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		13,3	0,85	6,4	5	0	CVPG	13,6	0,15	15%	11,5	15,7	5	
Other					7	0						7		
														3x 4/12, 4x 4/60
Sample B		5,79	0,83	14	12							12	12	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,42	0,074	1,4	5	0	CVPG	5,46	0,054	15%	4,64	6,28	5	

EQA round: E13/23 - Hormones 1

Deadline: 25.7.2023

Setup: groups - measurement principle, manufacturer of kit; Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Other					7	0	3x 4/12, 4x 4/60					7		
(122) Total T4	[nmol/L]				2							2	2	100
Sample A												2	2	100
Other					2	0	1x 4/1, 1x 4/12					2		
Sample B												2	2	100
Other					2	0	1x 4/1, 1x 4/12					2		
(124) Free T4	[pmol/L]				17							17	16	94
Sample A		19,1	4,1	22	17							17	16	94
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		16,5	0,82	5	7	0	CVPG	16,5	0,15	13%	14,3	18,7	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		23,7	1	4,3	6	0	CVPG	23,8	0,089	13%	20,7	26,9	6	
Other					4	0	4x 4/12					4		
Sample B		13,6	2,5	18	17							17	16	94
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		12,6	0,89	7,1	7	0	CVPG	12,4	0,11	13%	10,7	14,1	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		16,2	0,62	3,8	6	0	CVPG	16,5	0,065	13%	14,3	18,7	6	
Other					4	0	4x 4/12					4		
(305) Testosterone	[nmol/L]				9							9	8	89
Sample A		15,3	4	26	9							9	9	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		17,8	0,88	5	5	0	CVPG	17	0,11	22%	13,2	20,8	5	
Other					4	0	1x 4/1, 3x 4/12					4		
Sample B		44,5	11	25	9							9	8	89
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		51,3	1,1	2,1	5	0	CVPG	51,5	0,16	22%	40,1	62,9	5	
Other					4	0	1x 4/1, 3x 4/12					4		
(123) TSH	[mU/L]				17							17	17	100
Sample A		9,1	1,3	14	17							17	17	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		7,94	0,23	2,9	7	0	CVPG	8,08	0,054	14%	6,94	9,22	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,1	0,97	9,6	6	0	CVPG	10,2	0,038	14%	8,77	11,7	6	
Other					4	0	4x 4/12					4		
Sample B		32,5	4,4	14	17							17	17	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		29,2	1,4	4,7	7	0	CVPG	28,8	0,23	14%	24,7	32,9	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		36,4	3,7	10	6	0	CVPG	36,8	0,14	14%	31,6	42	6	
Other					4	0	4x 4/12					4		